NCT06747923RecruitingPhase 2
SB17170 Phase 2 Trial in IPF Patients
A Randomized, Double-blind, Placebo-controlled, Parallel, Multicenter, Exploratory Phase IIa Clinical Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Properties of SB17170 in Idiopathic Pulmonary Fibrosis (IPF) Patients.
Source: ClinicalTrials.gov · Last updated 19 Nov 2025
Brief summary (registry, in English)
This clinical trial is a 2:2:1 randomized, double-blind, placebo-controlled, parallel group, exploratory phase II trial. The main objective of this trial is to compare and evaluate change in FVC compared to placebo by administering SB17170 to moderate to severe patients with IPF. This clinical trial treatment involves administering SB17170 or placebo for 12 weeks.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 17 Dec 2024
- Start date
- 27 Jan 2025
- Primary completion date
- 30 May 2026
- Lead sponsor
- SPARK Biopharma
- Diseases
- Idiopathic pulmonary fibrosis
- NCT number
- NCT06747923
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 27 Jan 2025 to the primary completion date, 30 May 2026
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with confirmed acute exacerbation of IPF within 6 months prior to screening and/or during the screening period
- Patients who underwent major surgery within 3 months before screening or have major surgery planned during the clinical trial
- Patients who are unable to take drugs orally or have a history of major gastrointestinal surgery or pathological findings that may affect the absorption of the investigational product
Other illness
- When there is a primary disease showing UIP patterns (rheumatoid arthritis-related interstitial lung disease, connective tissue disease-related interstitial lung disease, etc.) and/or other clinically significant lung abnormalities
- Patients with lower respiratory tract infections requiring antibiotic treatment
- Patients with a history of malignancy or documented evidence of active or suspected malignancy within 5 years prior to screening
- Patients with evidence of active infection
- Patients with the following cardiovascular and cerebrovascular diseases at the time of screening:
- Severe hypertension within 3 months
- Myocardial infarction or unstable angina within 6 months
- History of thrombotic events within 6 months
- Diagnosis of heart failure within 6 months
- Patients with pulmonary hypertension
- Patients with Human Immunodeficiency Virus (HIV) infection or active hepatitis B or C
Who the study is looking for
- Adult male/female 40 years or older at the time of obtaining informed consent
- Patients diagnosed with idiopathic pulmonary fibrosis who meet the following criteria:
- Patients with idiopathic pulmonary fibrosis who are confirmed by chest High-Resolution Computed Tomography (HRCT) scan
- Patients with Usual Interstitial Pneumonia (UIP) or probable UIP HRCT pattern consistent with a diagnosis of idiopathic pulmonary fibrosis confirmed through central reading of chest HRCT before the baseline visit
- Patients with a history of idiopathic pulmonary fibrosis treatment who meet the defined criteria
- Patients with Forced Vital Capacity (FVC) ≥ 45% of the normal predicted value at the screening visit
- Patients meeting pulmonary function test criteria at the screening visit
- Patients who have received the explanation of this clinical trial and voluntarily agreed and signed the informed consent form
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Myong Ji Hospital Coordinator of this site? Confirm its status | Goyang | South Korea | Recruiting |
| Chung-Ang University Gwangmyeong Hospital Coordinator of this site? Confirm its status | Gwangmyeong | South Korea | Recruiting |
| Seoul Asan Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Not yet recruiting |
| The Catholic Univ. of Korea Seoul St. Mary's Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Not yet recruiting |
| Ajou University Hospital Coordinator of this site? Confirm its status | Suwon | South Korea | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.